The use of triple therapy regimens, often called highly active antiretroviral therapy (HAART),
generally involving 2 nucleoside analogues and an HIV protease inhibitor, have been …

The current standard of care in antiretroviral therapy includes two nucleoside analogue
reverse transcriptase inhibitors (NRTIs) plus a potent third agent, usually an HIV protease …

Protease inhibitors are still a cornerstone of combination antiretroviral therapy. A profound
knowledge of the unwanted, but manageable, effects of protease inhibitor therapy is …

Objective: To compare three possible therapeutic strategies for the treatment of patients with
an intermediate risk of HIV disease progression. Design: Mathematical modeling based on …

Risk factors in the development of adverse reactions in HIV-1-infected patients treated with
highly active antiretroviral therapy (HAART) containing protease inhibitors are poorly …

At present, the majority of patients who have initiated their first antiretroviral therapy have
received a combination comprising a nonnucleoside and two nucleoside analogues. The …

Recent progress in our understanding of the viral dynamics and immunobiology of HIV
infection, coupled with the introduction of a new generation of antiretroviral agents, has led …

The HIV protease (or proteinase) enzyme is an essential component of the replicative cycle
of HIV, performing the post-transitional processing of the gag and gag-pol gene products …

Objectives: To investigate the factors related to viral load becoming undetectable among
patients from Southern Alberta who started a protease inhibitor for the first time, and to …

The use of highly active antiretroviral therapy, the combination of at least three different
antiretroviral drugs for the treatment of HIV-1 infection, has greatly improved the prognosis …